Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống
1
/ 44 trang
THÔNG TIN TÀI LIỆU
Thông tin cơ bản
Định dạng
Số trang
44
Dung lượng
4,5 MB
Nội dung
Dyslipidemia Management in 2016 Michael Heffernan MD PhD FRCPC FACC Faculty/Presenter Disclosure • Faculty: Dr Michael Heffernan • Title of Talk: 2016 Dyslipidemia Update • Relationships with commercial interests: • Grants/Research Support: Bayer, Boehringer Ingelheim, Esai, AstraZeneca • Speakers Bureau/Honoraria: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Amgen, Servier, Sanofi • Consulting Fees: Bayer, AstraZeneca, Boehringer Ingelheim, Amgen, Sanofi • Other: None Objectives At the end of this presentation, the participant will be able to: Identify patients not at LDL-C goal despite current treatment and discuss why they would benefit from further LDL-C reduction Appraise clinical data and new treatment strategies to lower LDL-C in the high risk patient Discuss clinical management of the high risk patient not at goal and implementation of new treatment strategies The Case: John 56y male HTN, dyslipidemia Previous MI and angioplasty at age 48y Family history of premature CAD Non-‐smoker Exercises 100 min/week ALended cardiac rehab and adheres to dietary guidelines The Case Medica'ons − ASA 81 mg once daily − AtorvastaOn 20 mg − Bisoprolol 5 mg once daily − Ramipril 10 mg once daily Lipid Profile − TC: 5.9 mmol/L − TG:1.4 mmol/L − HDL-‐C: 1.4 mmol/L − LDL-‐C: 3.6 mmol/L (current) − non-‐HDL-‐C: 4.3 mmol/L − He has tried rosuvastaOn but was unable to tolerate it (mylagias) − He was on 40 mg of atorvastaOn however this also provoked myalgias − He can tolerate 20 mg of atorvastaOn What is John’s Target and Why Do We Want to Get Him There ? The Cholesterol Hypothesis Originated with Observational Studies Epidemiologic Data – Serum Cholesterol Levels and CHD MRFIT trial: age-adjusted CHD death rate and serum cholesterol in 361,662 US men (aged 35–57 years) Each 1% Increase in Total Cholesterol Level is associated with a 2% Increase in CHD Risk Martin MJ, et al Lancet 1986;2:933–936 Clinical Trials Validated The LDL Hypothesis 30 These trials have demonstrated that LDL-C lowering is associated with greater reduction of CHD events CHD Event Rate,% 25 Secondary Prevention 4S-P 20 4S-T 15 1O DIABETES PREVENTION Care-P Care-T 10 HPS-T PROS-T TNT-80 TNT-10 Ascot-T JUP-T 1.3 1.8 Lipid-T HPS-P PROS-P WPS-P AFCAPS-P CARDS-T Lipid-P 2.5 Primary Prevention JUP-P AFCAPS-T WPS-T Ascot-P 3.0 3.5 4.0 LDL-C mmol/L 4.5 5.0 5.4 @>4'(.:(24'$*2(&:%(8:$*2/&'/.:.[$Y@**Z$@4''&M42&O48T$V&8G(:T$PIHI\X]"SH"]ICH"5 years Additional populations ODYSSEY CHOICE II Patients with hypercholesterolemia on non-statin LMT or diet N=200; months ODYSSEY OPTIONS I Patients not at goal with moderate dose atorvastatin N=355; months ODYSSEY OPTIONS II Patients not at goal with moderate dose rosuvastatin N=305; months Interesting Concept, But Will It Help John ? OSLER: Evolocumab Plus Standard of Care Achieved a 61% Reduction in LDL-C over Standard of Care at 12 Weeks 3.6 3.1 mmol/L 3.1 2.6 61% reduction (95%CI 59-63%), P,$+48C?&:&'$67,$=&:&'$&8-$848C?&:&'$/.G>(%/G$.:24D(,$p8.:&M'($ &89/8&$2(i5/2/89$>4.0/:&'/d&O48T$VV*,$'/0/-C'4K(2/89$:>(2&0#$ † q$!P$K((D.$?42$&''$0&O(8:.$G48O85/89$:2(&:%(8:,$/8G'T$"I]$0&O(8:.$K>4$G4%0'(:(-$o](&2:$-/.(&.(T$^A6AT$HU]!\PXHY;ZSX"IcX($V/0/-$R(.(&2G>$@'/8/G.$@4248&2#$12/%&2#$12(3(8O48$*2/&'$2(.5':.T$^A6A$ HU[...]... NOT at LDL-C target1* ($ 2 mmol/L) !! 88% of patients received a ‘potent’ statin with suboptimal dose !! 14% of patients received additional lipid- lowering agent 43% Canadian patients with diabetes are NOT at LDL-C target2† ($ 2 mmol/L) !! 82% of patients were on a lipid- lowering agent g)/9>$2/.D$k$ g)/9>$2/.D$k$,./.#+/0!+/-(/0!)12(+2(3!4(/145(/+%!+/-(/1+%!)12(+2(3!,(/(6/.7+2,8%+/!)12(+2(3!)1+6(-(2!9(%%1-82!./!:/+91#$5+9!;!2,./(!?@ 5.0 mmol/L #!Familial hypercholesterolemia !50% reduction in LDL-C Alternate Target #!LDL-C > 3.5 mmol/L... from Jones P, et al for the CURVES Investigators Am J Cardiol 1998;81:582-587 Add-On Therapy has had Moderate Benefit in Further Lowering LDL-C Add-On Therapy$ LDL-C Lowering+ Niacin4-6$ 20% + Other Lipid Effects+ Outcome Data (Add-on to statin)+ " HDL by 30% # TG by 40%$ No benefit as addon to statin7,8$ " HDL-C (10-50%) # TG (20-50%) No benefit as add-on to statin$ Fibrates9,10$ 5 – 20%+ Bile Acid... (%) 50 40 Ezetimibe Fibrate Bile acid resin 30 Niacin Diet/unsat Fatty acid 20 Ileal bypass CTTC trials (statin) 10 IMPROVE-IT 0 0.3 0.5 0.8 1.0 1.3 1.5 Reduction in LDL-C (mmol/L) 1.8 2.1 Non-statin lipid- lowering studies suggest coronary event reduction is due to LDL-C reduction, independent of method @>4'(.:(24'$*2(&:%(8:$*2/&'/.:.[$@4''&M42&O48T$V&8G(:T$PII!\X""SHP"]CHP]($@4248&2#$B259$124b(G:$R(.(&2G>$W2450T$^A6AT$HU]!\PXHSX"IcX